US-Nasdaq-Tickersymbol:PCYC
D-Tickersymbol:PY2
Aktueller US-Kurs : $4,75
www.advfn.com/...pid=staticchart&s=N^PCYC&p=0&t=1&dm=0&vol=1&" style="max-width:560px" >
Aktueller D-Kurs : €4,00
chart.sbroker.is-teledata.com/...Sym=279697&hist=1d&volume=on" style="max-width:560px" >
1. KZ : $7,00
2. KZ : $8,00
3. KZ : $9,00
Kurs ist von $9,48 bis auf $3,26 gefallen,weil ein Lungenkrebsmedikament nicht die 3. Phase bestanden hat.
Pharmacyclics wird Xcytrin in drei weiteren Versuchen testen.
Desweiteren stehen versch. andere Medikamente in unterschiedlichen Phasen in der Pipeline.
Meiner Meinung ist dieses Unternehmen ein genaueren Blick wert.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer, atherosclerosis and other diseases. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at www.pharmacyclics.com. Pharmacyclics®, Xcytrin® and the " pentadentate" logo® are registered trademarks of Pharmacyclics, Inc.
www.tradesignal.com/cmy/forum/image.aspx?f=1&id=1442244" style="max-width:560px" >
D-Tickersymbol:PY2
Aktueller US-Kurs : $4,75
Aktueller D-Kurs : €4,00
1. KZ : $7,00
2. KZ : $8,00
3. KZ : $9,00
Kurs ist von $9,48 bis auf $3,26 gefallen,weil ein Lungenkrebsmedikament nicht die 3. Phase bestanden hat.
Pharmacyclics wird Xcytrin in drei weiteren Versuchen testen.
Desweiteren stehen versch. andere Medikamente in unterschiedlichen Phasen in der Pipeline.
Meiner Meinung ist dieses Unternehmen ein genaueren Blick wert.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer, atherosclerosis and other diseases. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at www.pharmacyclics.com. Pharmacyclics®, Xcytrin® and the " pentadentate" logo® are registered trademarks of Pharmacyclics, Inc.
